ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
3.450
+0.190 (5.83%)
At close: May 12, 2025, 4:00 PM
3.440
-0.010 (-0.29%)
After-hours: May 12, 2025, 7:54 PM EDT
Company Description
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound.
The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
ENDRA Life Sciences Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | May 9, 2017 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Alexander Tokman |
Contact Details
Address: 3600 Green Court, Suite 350 Ann Arbor, Michigan 48105-1570 United States | |
| Phone | 734 335 0468 |
| Website | endrainc.com |
Stock Details
| Ticker Symbol | NDRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681682 |
| CUSIP Number | 29273B104 |
| ISIN Number | US29273B3024 |
| Employer ID | 26-0579295 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Alexander Y. Tokman | Acting Chief Executive Officer and Chairman |
| Richard Jacroux | Chief Financial Officer and Secretary |
| Michael Thornton Ph.D. | Chief Technology Officer |
| Dr. Jonathan Behr Ph.D. | Co-Founder |
| Steve Freeman | Human Resources Leader |
| Ziad Rouag | Head of Regulatory and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2025 | 10-K/A | [Amend] Annual report |
| Apr 2, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 21, 2024 | 10-Q/A | [Amend] Quarterly report |
| Nov 19, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |